• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by ZyVersa Therapeutics Inc.

    4/17/25 4:31:13 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVSA alert in real time by email
    DEFA14A 1 formdefa14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to § 240.14a-12

     

    ZYVERSA THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):
     
    ☒ No fee required
    ☐ Fee paid previously with preliminary materials
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     
     

     

     

     
     

     

     

     

     

     

     

    Get the next $ZVSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZVSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

      KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects at risk of cardiometabolic diseases.Groundbreaking data demonstrating IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation — bot

      5/12/25 4:35:00 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

      WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100. CEO Stephen C. Glover issued a shareholder letter detailing the company's strategy to position IC 100 as a complementary therapy to GLP-1 agonists to treat obesity-associated cardiometabolic complications. Obesity: A Global Health Crisis with Unmet Medical Needs Obesity has reached pandemic proportions, affecting over 40% of Americans, with a projected increase to 51% of the global population within 12 years

      5/7/25 7:57:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative). Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation

      3/27/25 9:15:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

      SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

      11/14/24 6:01:27 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    SEC Filings

    See more
    • ZyVersa Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

      5/30/25 4:15:40 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by ZyVersa Therapeutics Inc.

      SCHEDULE 13G - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

      5/15/25 3:09:10 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ZyVersa Therapeutics Inc.

      10-Q - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

      5/12/25 4:37:07 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    Financials

    Live finance-specific insights

    See more
    • ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

      KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects at risk of cardiometabolic diseases.Groundbreaking data demonstrating IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation — bot

      5/12/25 4:35:00 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative). Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation

      3/27/25 9:15:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

      KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.Two obesity proof-of-concept studies with IC 100 in diet-induced obesity (DIO) mouse models are planned, which will include assessment of various metabolic parameters. At least one of the studies is targeted to begin Q4-2024.IC 100 Investigational New Drug (IND) submission is planned for Q2-2025, and once cleared, will be followed by

      11/14/24 8:10:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Freitag Gregory Gene

      4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

      7/18/24 9:35:08 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Finizio Robert G

      4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

      7/18/24 9:35:05 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Glover Stephen C.

      4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

      7/18/24 9:35:11 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care